{
    "clinical_study": {
        "@rank": "5079", 
        "brief_summary": {
            "textblock": "To determine the safety and efficacy of erythropoietin administered to patients with AIDS or\n      advanced AIDS related complex ARC and anemia."
        }, 
        "brief_title": "The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic", 
        "condition": [
            "HIV Infections", 
            "Cytopenias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "AIDS-Related Complex"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  History of any primary hematologic disease.\n\n          -  Clinically significant disease / dysfunction of the pulmonary, cardiovascular,\n             endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to\n             underlying HIV disease.\n\n          -  AIDS-related dementia.\n\n          -  Uncontrolled hypertension (diastolic blood pressure > 100 mmHg).\n\n          -  Presence of concomitant iron deficiency.\n\n          -  Anemia attributable to factors other than AIDS or zidovudine (AZT) therapy.\n\n          -  Acute opportunistic infection.\n\n          -  History of seizures.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT) during the double-blind phase of the study.\n\n        Patients with clinically significant disease / dysfunction of the pulmonary,\n        cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not\n        attributable to underlying AIDS are excluded.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Experimental drug or experimental device.\n\n          -  Cytotoxic chemotherapy.\n\n          -  Excluded within 2 months of study entry:\n\n          -  Androgen therapy.\n\n          -  Zidovudine (AZT) and during double-blind phase of study.\n\n        Clinical diagnosis of AIDS related anemia.\n\n          -  Clinical diagnosis of AIDS or advanced AIDS related complex (ARC).\n\n          -  Clinically stable for 1 month preceding study entry.\n\n        Substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002303", 
            "org_study_id": "004D", 
            "secondary_id": "H87-048"
        }, 
        "intervention": {
            "intervention_name": "Epoetin alfa", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "Erythropoietin", 
            "Acquired Immunodeficiency Syndrome", 
            "Anemia", 
            "AIDS-Related Complex", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Raritan", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "088690602"
                }, 
                "name": "Ortho Pharmaceutical Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in Patients With AIDS or Advanced ARC and Anemia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002303"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ortho Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1989"
    }, 
    "geocoordinates": {
        "Ortho Pharmaceutical Corp": "40.57 -74.633"
    }
}